Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918408 | 0.86 | SIGMAR1 (0.60) | SIGMAR1HTR1APARP1 | |
| SCHEMBL918431 | 0.86 | SIGMAR1 (0.60) | SIGMAR1HTR1APARP1 | |
| SCHEMBL9726233 | 0.81 | SIGMAR1 (0.61) | SIGMAR1HTR1A | |
| SCHEMBL10231292 | 0.80 | SIGMAR1 (0.68) | SIGMAR1HTR1A | |
| SCHEMBL917378 | 0.80 | HTR7 (0.38) | SIGMAR1 | |
| SCHEMBL3314489 | 0.78 | SIGMAR1 (0.46) | SIGMAR1 | |
| SCHEMBL9867159 | 0.78 | SIGMAR1 (0.60) | SIGMAR1HTR1A | |
| SCHEMBL5541146 | 0.78 | SIGMAR1 (0.60) | SIGMAR1HTR1A | |
| SCHEMBL9726237 | 0.78 | SIGMAR1 (0.60) | SIGMAR1HTR1A | |
| SCHEMBL14601668 | 0.78 | SIGMAR1 (0.60) | SIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | claimed |
| JP-4726304-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| US-7786174-B2 | Methods and compounds for inhibiting amyloid deposits | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-08-31 | — | — | US | claimed |
| US-7598269-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2009-10-06 | — | — | US | claimed |
| EP-1276483-B1 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | BELLUS HEALTH INT LTD (CH) | 2009-09-02 | — | — | EP | claimed |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-17 | — | — | US | claimed |
| JP-2007516939-A | — | — | 2007-06-28 | — | — | JP | claimed |
| US-20070015737-A1 | Compounds for inhibiting diseases and preparing cells for transplantation | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-18 | — | — | US | claimed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | claimed |
| EP-1644325-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2006-04-12 | — | — | EP | claimed |
| US-20050038117-A1 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-02-17 | — | — | US | claimed |
| WO-2004113275-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | claimed |
| JP-2003517458-A | — | — | 2003-05-27 | — | — | JP | claimed |
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | claimed |
| EP-1276483-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-01-22 | — | — | EP | claimed |
| EP-1237547-A2 | COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION | ISIS INNOVATION LIMITED (GB) | 2002-09-11 | — | — | EP | claimed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | claimed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | claimed |
| WO-2001003680-A2 | COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION | ISIS INNOVATION LIMITED (GB) | 2001-01-18 | — | — | WO | claimed |
| WO-2000064420-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038117-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | SIGMAR1 3810/4885HTR1A 2420/4885PARP1 3930/4885 |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | SIGMAR1 2251/4885HTR1A 3414/4885PARP1 3564/4885 |
| US-20070015737-A1 | Compounds for inhibiting diseases and preparing cells for transplantation | IAPP, IDE, APP | SIGMAR1 4785/4885HTR1A 4619/4885PARP1 4430/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SIGMAR1 3888/4885HTR1A 2510/4885PARP1 3977/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | SIGMAR1 3888/4885HTR1A 2510/4885PARP1 3977/4885 |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | SIGMAR1 3810/4885HTR1A 2420/4885PARP1 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.